TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Active DRUJ range of motion (pronation and supination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight-bearing ability in neutral and pronated position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prefrontal glutamate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate
Endpoint domain: Physiological/clinical
Primary endpoint: Muscle force change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Smartphone addiction scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of optical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients remaining below 5,000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Responders to the Gluten Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serious Device and/or Serious Procedure-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean LogMAR Binocular Photopic Distance Corrected Near Visual Acuity at 33 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent Antibody Status (Maximum Titer Level Experienced)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Potentially Immune-related Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of acute adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of late adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of venous congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pregnant women's perceived labor pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pregnant women's satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Additional inpatient neurosurgical procedure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients discharged home
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: In-patient mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Median Radiographic Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Resolution of MPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: yield of detection of familial hypercholesterolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of positive or negative amyloid PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Fecal Sodium Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Discontinued Study Treatment Due to an AE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient hospitalization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of patients completely recovered
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in self-assessment of nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient knowledge of their condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of use of educational materials
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of Potential Participants Screened for the Study Who Are Enrolled
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Enrolled Participants Retained at the End of the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurogenic Bowel Dysfunction (NBD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Early Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Molar Incisor Hypomineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Proportion of Subjects With All Target Lesions Cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of rare peritoneal surface malignancies
Endpoint domain: Mortality/survival
Primary endpoint: Predictive power of HFM-parameters regarding cardiovascular-based death
Endpoint domain: Mortality/survival
Primary endpoint: Predictive power of HFM-parameters regarding rehospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity and specificity of chest x-ray and PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Residence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of adverse events during the treatment and follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Minutes of moderate-to-vigorous physical activity per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive predictive value of sonographic detection of pancreatic stents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Specimens with Histologic Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-relapse mortality at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Net adverse clinical and cerebral events (NACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Altered Dicer Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axis length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral cortex activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BARC expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy as assessed by plaque Psoriasis Area and Severity Index (PASI) scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Cystine Supersaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving ≥ 1-Stage Improvement in Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percent of Patients in Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device-oriented Composite Endpoint (DoCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of tasimelteon and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of tasimelteon as measured by spontaneous reporting of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in PC20NKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood level of immunologic biomarker PLox/apoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Remission of type 2 Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative Bioavailability of Xisimin Compared With Clarityne
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of in transit melanoma metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of pertussis disease
Endpoint domain: Mortality/survival
Primary endpoint: Patient Global Index of Improvement scale (PGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Junctional stability between device and abutment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of BMI from baseline at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of good-quality blastocysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleeding free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in circulating FVIII activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of PNT2258
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days of wheelchair use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Daily distance traveled
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average speed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Achilles peritendinous concentrations of pro-collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amino Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Glucose Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual analogue scale (VAS) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Gestational Diabetes Mellitus (GDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modelled cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in weight in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to supplementation regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Agreement between actual and estimated blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of post biopsy urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: normalized absolute change in total atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Taste/Palatability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic accuracy of radiographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fractional calcium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stage of change for cardiovascular risk-related behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported cardiovascular health behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical accuracy data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30-seconds chair stand test (30-sec CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Progressive Disease at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of non-serious and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: survival after 30 days
Endpoint domain: Mortality/survival
Primary endpoint: fatal and non-fatal coronary events
Endpoint domain: Mortality/survival
Primary endpoint: Lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Localized Sentinel Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of Headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lateral Trunk Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee to Hip Sagittal Plane Moment Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knee Abduction Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Foot Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vertical Ground Reaction Force (VGRF) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of QOL and symptom topics being addressed
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of QOL and symptom information being documented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of appropriate symptom interventions recommended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of pathologic complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients Experiencing Grade 3 or 4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Experiencing Grade 3 or 4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the blood sugar and blood lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients requiring packed Red Blood Cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of healthy volunteers with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number participants with non-cirrhotic chronic Hepatitis B with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in patients' ctDNA longitudinal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to first occurrence of keratitis or Iritis
Endpoint domain: Adverse events/effects
Primary endpoint: MRI ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: morphine dosage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physician's Global Assessment (PGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in the number of evacuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in pad weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of Streptococcus pseudopneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Survival-free rate of thromboembolic and hemorrhagic events
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Glucose Sensor Readings That Met Accuracy Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of GABHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adiposity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Becks Depression Inventory-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brunnsviken Brief Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Perfused Boundary Region (PBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Prasugrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of Prasugrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adrenal suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Remission of Renal Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in mean Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients operated with knee alloplasty
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease From the Baseline GCSI of at Least 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical clinical attachment level (VCAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical pocket depth (VPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Furcation horizontal component (FHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of the startle reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: First access success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AD Symptom Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With SIBO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude Pulmonary Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of Koning breast CT-guided biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occupational Engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of at least 10% reduction in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Services Assessment for Children and Adolescents (SACA)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of participants with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Personal Accomplishment Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depersonalization Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Emotional Exhaustion Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients at clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Control of Pelvic Floor Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Sodium Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Potassium Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Chloride Blood Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Talazoparib Following Single Oral Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Talazoparib Following Single Oral Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-Life (t1/2) of Talazoparib Following Single Oral Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes